Get this report today!
Table of Contents
Angioedema – Pipeline Review, H1 2012
Global Markets Direct’s, 'Angioedema - Pipeline Review, H1 2012', provides an overview of the Angioedema therapeutic pipeline. This report provides information on the therapeutic development for Angioedema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Angioedema. 'Angioedema - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Angioedema.
- A review of the Angioedema products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Angioedema pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Angioedema.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Angioedema pipeline depth and focus of Angioedema therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Talk to Robyn
+1 718 213 4904
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is ...
MediPoint: Drug-Eluting Balloons - Global Analysis and Market Forecasts Summary GlobalData has released its medical devices report, “MediPoint: Drug-Eluting Balloons - Global Analysis and Market Forecasts”. ...
MediPoint: Renal Denervation - Global Analysis and Market Forecasts Summary Numerous medical device news sources and industry executives have proclaimed renal denervation to be the top medical device breakthrough ...
... To differences in known breast cancer risk factors such as reproductive hormonal factors including age at first birth or menarche and breastfeeding click to edit master subtitle style 08/11/2013 risk factors ...
... Guidelines say People with diabetes and hypertension should be treated to a systolic blood pressure goal of 140 mmhg. Lower systolic targets (such as ...
... Are also less likely to participate in cancer screening source: devaux and de looper (2012) 2009 (or nearest year) breast cancer screening in past two years cervical cancer screening in past three ...
Reportlinker.com © Copyright 2013. All rights reserved.